瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效分析

Therapeutic Effect of Rosuvastatin and Atorvastatin on Coronary Heart Disease

目的探讨瑞舒伐他汀、阿托伐他汀在冠心病临床治疗中的应用效果。方法选择2018年5—12月期间,枣庄矿业集团中心医院心内科收治的90例冠心病患者为研究对象,遵循随机双盲法的要求划分为实验组(45例)与对照组(45例);对照组临床治疗方案为阿托伐他汀,实验组临床治疗方案为阿托伐他汀+瑞舒伐他汀,比对两组患者治疗前后血脂水平、治疗有效率以及不良反应发生率。结果治疗前两组患者的血脂水平趋同,差异无统计学意义(P>0.05);治疗后,实验组血脂水平改善明显,与对照组进行比对分析,差异有统计学意义(P<0.05);实验组的临床治疗有效率为91.11%,对照组的临床治疗有效率为68.89%,比对分析两组数据,差异有统计学意义(χ^2=6.944,P<0.05);实验组出现消化不良、便秘、腹胀腹痛等不良反应的概率为20.00%,对照组出现上述不良反应的概率为40.00%,组间差异有统计学意义(χ^2=4.286,P<0.05)。结论联合使用阿托伐他汀、瑞舒伐他汀对冠心病患者进行临床治疗,可以有效改善患者血脂水平,同时还能减少患者出现不良反应的概率,安全性较好,具有推广使用价值。

Objective To investigate the effect of rosuvastatin and atorvastatin in the clinical treatment of coronary heart disease. Methods From May to December 2018, 90 patients with coronary heart disease admitted to the Department of Cardiology, Central Hospital of Zaozhuang Mining Group were selected as experimental subjects, and were divided into experimental group (45 cases) and control group (45 cases) according to the requirements of random double-blind method;the control group was treated with atorvastatin, and the experimental group was treated with atorvastatin + rosuvastatin. The blood lipid levels, treatment efficiency and adverse reaction rate were compared before and after treatment. Results The blood lipid levels of the two groups before treatment were similar, the difference was not statistically significant(P>0.05). After treatment, the blood lipid level of the experimental group improved significantly, and the comparison was compared with the control group. The difference was statistically significant (P<0.05). The clinical effective rate of the experimental group was 91.11%, and the clinical effective rate of the control group was 68.89%. The data of the two groups were compared and the statistical significance was established (χ^2=6.944, P<0.05). The probability of adverse reactions such as indigestion, constipation, abdominal distension and abdominal pain was 20.00%, and the probability of occurrence of the above adverse reactions in the control group was 40.00%. There was statistically significant difference between the groups (χ^2=4.286, P<0.05). Conclusion The combination of atorvastatin and rosuvastatin for the treatment of patients with coronary heart disease can effectively improve the blood lipid level of patients, and the effect is more accurate. At the same time, it can reduce the probability of adverse reactions in patients, and it has good safety and promotion value.